» Articles » PMID: 14642927

Melanoma in Children and Adolescents

Overview
Journal Eur J Cancer
Specialty Oncology
Date 2003 Dec 4
PMID 14642927
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Childhood and adolescent melanoma is rare, accounting for only 1.3% for all cases of cancer in patients under the age of 20 years. However, in 15-19 year olds, melanoma accounts for up to 7% of all cancers. Review of reported cases in this age group reveals that predisposing 'paediatric' conditions such as a giant congenital melanocytic naevi or xeroderma pigmentosum are rarely present. Furthermore, inactivating germ-line mutations of the gene CDKN2A have only been reported in 1.5% of cases of early onset melanoma. Epidemiological studies suggest that interactions between solar exposure, development of naevi, pigmentary traits, and a family history of melanoma are the main determinants of melanoma development during the first 20 years of life. As yet, there are no available staging or treatment strategies for this group of patients so treatment recommendations are based on the adult experience. To improve our understanding of the natural history of melanoma and to identify the most appropriate therapies for young patients with this disease, practising physicians are encouraged to enroll their patients, especially those with advanced stage disease, in cooperative group trials which incorporate newer staging systems and promising therapies.

Citing Articles

Pediatric cancer predisposition syndromes involving non-central nervous system solid pediatric tumors: a review on their manifestations with a focus on histopathology.

Schurink B, Reyes-Mugica M, de Krijger R Virchows Arch. 2025; 486(1):3-21.

PMID: 39847050 PMC: 11782299. DOI: 10.1007/s00428-025-04029-1.


Regional lymph node evaluation in pediatric conventional melanoma subtype: a single-center 10-year review.

Sutthatarn P, Davidoff A, Bahrami A, Richard C, Shalini B, Santiago T Pediatr Surg Int. 2024; 40(1):68.

PMID: 38441654 PMC: 10914839. DOI: 10.1007/s00383-024-05646-8.


Rapid disease progression on immune checkpoint inhibitors in young patients with stage IV melanoma.

Machiraju D, Schafer S, Beckhove P, Roth J, Schulz C, Hassel J Front Med (Lausanne). 2023; 10:1117816.

PMID: 36756176 PMC: 9899839. DOI: 10.3389/fmed.2023.1117816.


International Society of Paediatric Surgical Oncology (IPSO) Surgical Practice Guidelines.

Abib S, Chui C, Cox S, Abdelhafeez A, Fernandez-Pineda I, Elgendy A Ecancermedicalscience. 2022; 16:1356.

PMID: 35510137 PMC: 9023308. DOI: 10.3332/ecancer.2022.1356.


Immunotherapy in Adolescents and Young Adults: What Remains in Cancer Survivors?.

Tanda E, Croce E, Spagnolo F, Zullo L, Spinaci S, Genova C Front Oncol. 2021; 11:736123.

PMID: 34631569 PMC: 8495150. DOI: 10.3389/fonc.2021.736123.